Printer Friendly

INTERPHARM DENIES THAT ITS INTERLEUKIN-6 HAS ENTERED CLINICAL TRIALS

INTERPHARM DENIES THAT ITS INTERLEUKIN-6 HAS ENTERED CLINICAL TRIALS
 NESS ZIONA, ISRAEL, April 6 /PRNewswire/ -- "The drug Interleukin- 6 produced by InterPharm Laboratories is still in the development and experimental stages in animals only and has not yet reached the clinical testing stage in humans," said Dr. Yoram Karmon, president and chief executive officer of InterPharm Laboratories Ltd. (NASDAQ: IPLLF).
 Dr. Karmon emphasized that the recent publications appearing in the Israeli press reporting that Interleukin-6, developed by InterPharm Labs, was being tested on human beings is absolutely incorrect and may mislead and raise false hopes for patients requesting to try the drug.
 Interleukin-6 (IL-6), produced by genetic engineering processes, is being developed by InterPharm Laboratories. This substance may be effective in the treatment of thrombocytopaenia, a condition of blood platelet loss frequently experienced by cancer patients undergoing chemotherapy and radiotherapy.
 InterPharm Laboratories is a subsidiary of Ares-Serono S.A., an international developer and marketer of ethical pharmaceutical and diagnostic products. The company's executive headquarters are in Geneva, Switzerland and its operational headquarters are in Boston. Ares-Serono has subsidiaries and manufacturing facilities in more than 20 countries. InterPharm shares are traded over-the-counter in the United States.
 -0- 4/6/92
 /CONTACT: Gina Cella of Ares-Serono, 617-982-900, ext. 251/
 (IPLLF) CO: Ares-Serono ST: Massachusetts IN: MTC SU:


DD -- NE014 -- 5453 04/06/92 15:03 EDT
COPYRIGHT 1992 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1992 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Apr 6, 1992
Words:224
Previous Article:DELL INTRODUCES HIGH-PERFORMANCE DESKTOP WITH NEW PROCESSOR-DIRECT GRAPHICS TECHNOLOGY
Next Article:LTV RECEIVES MLRS CONTRACT FOR NATIONAL GUARD BATTALION


Related Articles
INTERPHARM LABORATORIES REPORTS AN INCREASE IN SALES AND NET INCOME IN 1991
INTERPHARM LABORATORIES LTD. REPORTS REVENUES AND NET INCOME FOR THE SECOND QUARTER OF 1993
INTERPHARM LABORATORIES LTD. REPORTS LEGAL ACTION
TEL-AVIV COURT DENIES SHAREHOLDERS' REQUEST TO NULLIFY INTERPHARM'S LICENSE AGREEMENT
INTERPHARM LABORATORIES LTD. REPORTS 1993 RESULTS OF OPERATIONS
INTERPHARM LABORATORIES LIMITED REPORTS 1994 FIRST QUARTER RESULTS
ARES-SERONO S.A. EXTENDS TENDER OFFER FOR INTERPHARM LABORATORIES
NEGOTIATIONS CONCERNING r-hIFN-beta RESUMED, INTERPHARM LABORATORIES ANN0UNCES
RESTRAINING ORDER AGAINST ARES-SERONO, INTERPHARM LABORATORIES ANNOUNCES
RESTRAINING ORDER AGAINST ARES-SERONO S.A. HAS BEEN MODIFIED

Terms of use | Copyright © 2016 Farlex, Inc. | Feedback | For webmasters